Evidence map›Paper›PMID 41360519›Full record

ArticleChemMedChem2026

Design, Synthesis, and Evaluation of Novel Inhibitors of Aminoglycoside-Resistance 16S Ribosomal RNA Methyltransferases.

Benjamin E Deprez, Debayan Dey, Natalia Zelinskaya, Erika E Csatary, Qimin Winnie Yang, Minhua Nie, Graeme L Conn, William M Wuest

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Benjamin E DeprezDepartment of Chemistry, Emory University, Atlanta, Georgia, 30322, USA.
Debayan DeyDepartment of Biochemistry, Emory University School of Medicine, Atlanta, Georgia, 30322, USA.
Natalia ZelinskayaDepartment of Biochemistry, Emory University School of Medicine, Atlanta, Georgia, 30322, USA.
Erika E CsataryDepartment of Chemistry, Emory University, Atlanta, Georgia, 30322, USA.
Qimin Winnie YangDepartment of Chemistry, Emory University, Atlanta, Georgia, 30322, USA.
Minhua NieDepartment of Chemistry, Emory University, Atlanta, Georgia, 30322, USA.
Graeme L ConnDepartment of Biochemistry, Emory University School of Medicine, Atlanta, Georgia, 30322, USA.ORCID https://orcid.org/0000-0002-2419-380X
William M WuestDepartment of Chemistry, Emory University, Atlanta, Georgia, 30322, USA.ORCID https://orcid.org/0000-0002-5198-7744

Funding

RNA modification and antibiotic resistanceR01AI088025 · NIAID · EMORY UNIVERSITY · PI Graeme L Conn, Christine M Dunham · 2010 to 2026
$7.9M
Natural Product-Inspired Approaches Toward The Development Of Antivirulence And Species-Specific InhibitorsR35GM119426 · NIGMS · TEMPLE UNIV OF THE COMMONWEALTH · PI William M Wuest · 2016 to 2026
$4.8M
Atlanta Network for Training In KUH Scientific Research (ATLANTIS)TL1DK136047 · NIDDK · EMORY UNIVERSITY · PI Vivien Andrea Sheehan · 2022 to 2026
$3.0M
NIAID NIH HHS AI088025NIAID NIH HHS R01 AI088025NIDDK NIH HHS DK136047NIDDK NIH HHS TL1 DK136047NIGMS NIH HHS GM119426NIGMS NIH HHS R35 GM119426
6 · The paper itself

Abstract

One of the major mechanisms of resistance to ribosome-targeting antibiotics is the modification of ribosomal RNA (rRNA). Specific methyltransferase enzymes, for example, confer high-level resistance to aminoglycosides by selectively methylating the 16S rRNA in the ribosomal decoding center. These enzymes have been detected globally and pose a threat to the continued use of aminoglycosides. Compound 1, a dehydroamino amide inhibitor of the m

Indexed as

AminoglycosidesAnti-Bacterial AgentsDrug DesignEnzyme InhibitorsMethyltransferasesRNA, Ribosomal, 16SDose-Response Relationship, DrugDrug Resistance, BacterialEscherichia coliEscherichia coli ProteinsMicrobial Sensitivity TestsMolecular Docking SimulationMolecular StructureStructure-Activity RelationshipAminoglycosidesAnti-Bacterial AgentsEnzyme InhibitorsEscherichia coli ProteinsMethyltransferasesNpmA protein, E coliRNA, Ribosomal, 16Saminoglycosidesantibioticsmolecular modeling molecular dynamicsstructure–activity relationships

Identifiers

PMID41360519
PMCPMC12698113

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.